Abstract:Reduced fibrinolytic activity has been described in primary antiphospholipid syndrome (PAPS) and may be responsible for thrombotic events. Some evidence supports a relationship between anti-plasminogen (PLG) antibodies, anti-β2-glycoprotein 1 (β2GP1) antibodies, and fibrinolysis, but their relationship is still unclear. The aim of study is to evaluate the association between IgG anti-β2GP1 and IgG anti-PLG antibodies and thrombosis. Two groups of consecutive patients with PAPS and systemic lupus erythematosus (SLE): 32 patients with lupus anticoagulant (LAC), 32 patients without LAC, and 40 healthy controls were included. IgG against β2GP1 and PLG antibodies were measured by enzyme-linked immunosorbent assay, and a value above the 99th percentile of the normal healthy control was considered as positive, and their interrelationship with thrombosis was evaluated by Pearson Chi-squared test. Cross-reactive antibodies binding to PLG and β2GP1 were determined in a competitive and cross-inhibition assay. Levels of fibrinolytic activity in the presence of IgG fractions from patients and healthy controls were examined using a plasmin fluorogenic substrate assay. A high frequency of IgG anti-PLG antibodies (35.9%) was found in 64 patients, and its presence was associated with thrombosis (p = 0.001), which may be due to its ability to inhibit exogenous fibrinolysis. Coexistence of IgG anti-PLG and IgG anti-β2GP1 antibodies was found in 11 of 64 patients and was related with thrombosis (p = 0.001). Cross-reactive antibody binding to PLG and β2GP1 was found in IgG fractions from three patients and a monoclonal anti-β2GP1 antibody BD4, and one of these three patients had thrombotic history. However, no significant association was found between IgG anti-PLG and IgG anti-β2GP1 antibodies in patients. In conclusion, the prevalence of IgG anti-PLG was high in patients with PAPS and SLE and might relate with thrombosis. Cross-reactivity of IgG anti-β2GP1 antibodies with PLG may occur in the sera of patients.

Insight into the Hypercoagulable State of High‐risk Thrombotic APS Patients: Contribution of Aβ2gpi and Aps/pt Antibodies

Antibody Profiles Comprising Anti Phosphatidylserine/prothrombin Differently Affect Thrombin Generation and Protein C Resistance in Antiphospholipid Antibody Carriers

The Expression of Anti-TFPI Antibody in Antiphospholipid Syndrome and Its Clinical Signiifcance

Antiphospholipid Syndrome: Reversal of Antiphosphatidylserine/prothrombin-Induced Activated Protein C Resistance

Antiphospholipid syndrome: Reversal of antiphosphatidylserine/prothrombin-induced activated protein C resistance.

Anti-phosphatidylserine/prothrombin complex antibodies (aps/pt) increase the risk for thrombosisbased on lupus anticoagulantpositivity

Anti-phosphatidylserine/prothrombin Complex Antibodies (aps/pt) Increase the Risk for Thrombosis Based on Lupus Anticoagulant Positivity

Anti-2GPI domain 1 antibodies stratify high risk of thrombosis and late pregnancy morbidity in a large cohort of Chinese patients with antiphospholipid syndrome

Clinical Performance of Antibodies to Prothrombin and Thrombin in Chinese Patients with Antiphospholipid Syndrome: Potential Interest in Discriminating Patients with Thrombotic Events and Non-Thrombotic Events

Antibodies to phosphatidylserine/prothrombin (aPS/PT) enhanced the diagnostic performance in Chinese patients with antiphospholipid syndrome.

Evaluation of the Diagnostic Potential of Antibodies to Beta2-Glycoprotein 1 Domain 1 in Chinese Patients with Antiphospholipid Syndrome

Tetra Positive Thrombotic Antiphospholipid Syndrome: Major Contribution of Anti‐phosphatidyl‐serine/prothrombin Antibodies to Lupus Anticoagulant Activity

Prevalence of Aphosphatidylserine/prothrombin Antibodies and Association with Antiphospholipid Antibody Profiles in Patients with Antiphospholipid Syndrome: A Systematic Review and Meta-Analysis.

Diagnostic Value of Antibodies to Phosphatidylserine/prothrombin Complex for Antiphospholipid Syndrome in Chinese Patients

Thrombin generation assay and lupus anticoagulant synergically distinguish populations of patients with antiphospholipid antibodies

Thrombosis in Antiphospholipid Syndrome: Current Perspectives and Challenges in Laboratory Testing for Antiphospholipid Antibodies

IgG Antibodies to Plasminogen and Their Relationship to IgG Anti-Β 2 -Glycoprotein 1 Antibodies and Thrombosis

Anti-phosphatidyl-serine/prothrombin antibodies (aPS/PT) in isolated lupus anticoagulant (LA): is their presence linked to dual test positivity?

Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome

Anti-domain 1 β2 glycoprotein antibodies increase expression of tissue factor on monocytes and activate NK Cells and CD8+ cells in vitro

Clinical significance and prevalence of some coagulation-related factors' antibodies in patients with antiphospholipid syndrome or systemic lupus erythematosus with thrombosis